Officer Sale of Krystal Biotech, Inc. Common Stock

EVP, General Counsel John Charles sold 642 shares of Krystal Biotech, Inc. common stock on May 26, 2026, at a price of $302.03 per share. The sale was conducted under a Rule 10b5-1 trading plan adopted on February 23, 2026, which is set to terminate on December 31, 2026, or earlier upon completion of the stock sale. Following the transaction, Mr. Charles no longer directly owns shares in the company. The filing also notes that the trading plan will terminate earlier if all shares subject to the plan are sold.